Cuprina Holdings (CUPR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$38,800.84

Revenue (quarter)

$38,800.84

Revenue growth (year over year)

+9.70%

Gross profit (trailing twelve months)

−$501.59

Gross margin

−1.29%

Net income (trailing twelve months)

−$3.6M

Net income (quarter)

−$3.6M

Net income growth (year over year)

−218.18%

Net margin

−9366.75%

Return on equity

−1089.60%

EPS (trailing twelve months)

−$1.42

Book value per share

$1.47

P/E (trailing twelve months)

—

Price to book

3.38

Debt to assets

40.56%

Payout ratio

—

Dividend yield

—

Company profile

Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.

• Is Cuprina Holdings (CUPR) profitable?

  No. Cuprina Holdings reported a net loss of $3.6M over the trailing twelve months.

• How much revenue does Cuprina Holdings (CUPR) make?

  Cuprina Holdings generated $38,800.84 in revenue over the trailing twelve months, up 9.70% year over year.

• How do I buy stock in Cuprina Holdings (CUPR)?

  CUPR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.